Comparable stake leader
City Hill, LLC
SEC ownership of Erasca, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001761918.
Disclosed value leader
City Hill, LLC
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- ERAS on Nasdaq
- Parsed ownership sources
-
13D/G and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
City Hill, LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
City Hill, LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001761918
- Issuer location
- San Diego, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Erasca, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
City Hill, LLC
Disclosed value leader
City Hill, LLC
Comparable rows
50/50
Latest evidence
30 Jun 2026
13D/G
13F
Lead comparable stake: 10%
13D/G row: City Hill, LLC
Showing 1-8 of 50 holder rows.
Quick read
City Hill, LLC leads the comparable SEC ownership view at 10%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens City Hill, LLC's linked filing trail.
Comparable ownership
Top 5
City Hill, LLC
10%
T. Rowe Price Investment Manageme...
6.8%
Venrock Healthcare Capital Partne...
5.3%
Frazier Life Sciences Public Fund...
5.3%
RTW INVESTMENTS, LP
5.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| City Hill, LLC |
13D/G
Jonathan E. Lim
|
10%
|
$697,595,331
36,968,486 shares
|
$0 | 30 Jun 2026 |
| T. Rowe Price Investment Management, Inc. |
13F
13D/G
Company
|
6.8%
from 13D/G
|
$388,125,000
21,185,839 shares
|
— | 30 Jun 2026 |
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
5.3%
|
$284,405,616
16,382,812 shares
|
$0 | 31 Mar 2026 |
| Frazier Life Sciences Public Fund, L.P. |
13D/G
|
5.3%
|
$21,355,029
15,038,753 shares
|
-$10,702,679 | 30 Jun 2025 |
| RTW INVESTMENTS, LP |
13F
13D/G
Company
|
5.2%
from 13D/G
|
$328,784,533
17,946,754 shares
|
— | 30 Jun 2026 |
| Logos Global Management LP |
13F
13D/G
Company
|
4.8%
from 13D/G
|
$222,588,000
12,150,000 shares
|
— | 30 Jun 2026 |
| NOVARTIS PHARMA AG |
13D/G
|
4.4%
|
$17,107,692
12,307,692 shares
|
$0 | 31 Dec 2024 |
| Paradigm Biocapital Advisors LP |
13D/G
13F
Company
|
3.3%
|
$180,417,307
10,392,702 shares
|
-$82,744,582 | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$2,283,572.
Buys
$0
Insiders: 0
Sells
$2,283,572
Insiders: 2
Net
-$2,283,572
Shares: -220,000
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 220,000
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 100,000 | $0 | $1,612,760 | -$1,612,760 |
| 6-9 | 0 | 120,000 | $0 | $670,812 | -$670,812 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-15 of 15 reporting-owner rows connected to Erasca, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
15
Largest Forms 3/4/5 holder
ARCH Venture Partners X, LLC
Net 12M change
-$2,283,572
Latest report
10 Aug 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| ARCH Venture Partners X, LLC | 10%+ Owner | $17,572,804 | Mixed | 20 Jul 2021 | ||
| Bihua Chen | Director | $17,187,655 | Mixed | 22 Jun 2023 | ||
| Lin Wei | Chief Medical Officer | $501,983 | Mixed | 01 Feb 2023 | ||
| Ebun Garner | Chief Legal Officer | $411,246 | -$1,982,812 | -83% | Filing P/S | 01 Apr 2026 |
| David M. Chacko | CFO and CBO | $334,380 | Mixed | 15 Dec 2025 | ||
| Pratik S. Multani | Director | $257,570 | Mixed | 26 Jun 2026 | ||
| Shannon Morris | Chief Medical Officer | $0 | -$300,760 | -100% | Mixed | 04 Mar 2026 |
| Jean I. Liu | Director | Mixed | 26 Jun 2026 | |||
| Charles S. Fuchs | President, R&D | Mixed | 10 Aug 2026 | |||
| Alexander W. Casdin | Director | Mixed | 26 Jun 2026 | |||
| Jonathan E. Lim | Chairman & CEO, Director, 10%+ Owner | Mixed | 29 Jan 2026 | |||
| Julie Hambleton | Director | Mixed | 26 Jun 2026 | |||
| Michael David Varney | Director | Mixed | 29 Jan 2026 | |||
| James Arthur Bristol | Director | Mixed | 26 Jun 2026 | |||
| Valerie Denise Harding Start | Director | Mixed | 26 Jun 2026 |
Recent insider transactions for Erasca, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Charles S. Fuchs | ERAS | Stock option (right to buy) | Award | 1,300,000 | 1,300,000 | 10 Aug 2026 | Direct | |||
| Valerie Denise Harding Start | ERAS | Stock option (right to buy) | Award | 29,888 | 29,888 | 26 Jun 2026 | Direct | |||
| Jean I. Liu | ERAS | Stock option (right to buy) | Award | 29,888 | 29,888 | 26 Jun 2026 | Direct | |||
| Pratik S. Multani | ERAS | Stock option (right to buy) | Award | 29,888 | 29,888 | 26 Jun 2026 | Direct | |||
| Alexander W. Casdin | ERAS | Stock option (right to buy) | Award | 29,888 | 29,888 | 26 Jun 2026 | Direct | |||
| Julie Hambleton | ERAS | Stock option (right to buy) | Award | 29,888 | 29,888 | 26 Jun 2026 | Direct | |||
| James Arthur Bristol | ERAS | Stock option (right to buy) | Award | 29,888 | 29,888 | 26 Jun 2026 | Direct | |||
| Ebun Garner | ERAS | Common Stock | Sale | -76.1% | $1,312,000 | $16.40 | -80,000 | 25,076 | 01 Apr 2026 | Direct |
| Ebun Garner | ERAS | Common Stock | Options Exercise | 319% | 80,000 | 105,076 | 01 Apr 2026 | Direct | ||
| Ebun Garner | ERAS | Stock Option (right to buy) | Options Exercise | -22.2% | -80,000 | 280,000 | 01 Apr 2026 | Direct | ||
| Shannon Morris | ERAS | Common Stock | Sale | -100% | $300,760 | $15.04 | -20,000 | 0 | 04 Mar 2026 | Direct |
| Shannon Morris | ERAS | Common Stock | Options Exercise | 20,000 | 20,000 | 04 Mar 2026 | Direct | |||
| David M. Chacko | ERAS | Stock option (right to buy) | Award | 640,000 | 640,000 | 29 Jan 2026 | Direct | |||
| Shannon Morris | ERAS | Stock option (right to buy) | Award | 625,000 | 625,000 | 29 Jan 2026 | Direct | |||
| Michael David Varney | ERAS | Stock option (right to buy) | Award | 96,000 | 96,000 | 29 Jan 2026 | Direct | |||
| Ebun Garner | ERAS | Stock option (right to buy) | Award | 560,000 | 560,000 | 29 Jan 2026 | Direct | |||
| Jonathan E. Lim | ERAS | Stock option (right to buy) | Award | 2,000,000 | 2,000,000 | 29 Jan 2026 | Direct | |||
| Ebun Garner | ERAS | Common Stock | Sale | -82.7% | $670,812 | $5.59 | -120,000 | 25,076 | 07 Jan 2026 | Direct |
| Ebun Garner | ERAS | Common Stock | Options Exercise | 478.6% | 120,000 | 145,076 | 07 Jan 2026 | Direct | ||
| James Arthur Bristol | ERAS | Stock Option (right to buy) | Award | 37,762 | 37,762 | 01 Jan 2026 | Direct | |||
| Jean I. Liu | ERAS | Stock Option (right to buy) | Award | 20,617 | 20,617 | 01 Jan 2026 | Direct | |||
| Pratik S. Multani | ERAS | Stock Option (right to buy) | Award | 19,532 | 19,532 | 01 Jan 2026 | Direct | |||
| Valerie Denise Harding Start | ERAS | Stock Option (right to buy) | Award | 24,306 | 24,306 | 01 Jan 2026 | Direct | |||
| Alexander W. Casdin | ERAS | Stock Option (right to buy) | Award | 23,872 | 23,872 | 01 Jan 2026 | Direct | |||
| David M. Chacko | ERAS | Common Stock | Other | 6.79% | 17,793 | 279,980 | 15 Dec 2025 | Direct | ||
| Ebun Garner | ERAS | Common Stock | Award | 18.4% | 3,902 | 25,076 | 15 Dec 2025 | Direct |
* marks a reported price that did not pass the local price check.